Patents Assigned to Biocompatibles UK Limited
-
Patent number: 8366598Abstract: A therapeutic strand implant, for use in brachytherapy and deliverable to an implant site by way of a needle, includes a plurality of radioactive sources, and a polymeric material molded to encapsulate the radioactive sources. A space is defined by the polymeric material between each adjacent pair of the radioactive sources. A plurality of protrusions is defined by an outer surface of the encapsulating polymeric material.Type: GrantFiled: August 18, 2011Date of Patent: February 5, 2013Assignee: Biocompatibles UK LimitedInventors: Gary A. Lamoureux, James Matons, Warren W. Johnston, Matthew Bouffard, Warren Rice
-
Publication number: 20120276151Abstract: An embolic composition comprises microspheres formed of water-insoluble water-swellable anionic polymer having swollen diameter more than 100 ?m and a cationic camptothecin compound, preferably irinotecan. The microspheres are preferably formed of crosslinked polyvinylalcohol, preferably of ethylenically unsaturated polyvinylalcohol macromer, crosslinked with anionic ethylenically unsaturated anionic comonomer. The compositions are used to treat hypervascular tumours for instance colorectal metastases of the liver.Type: ApplicationFiled: October 27, 2011Publication date: November 1, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard Lewis, Peter William Stratford, Maria Victoria Gonzalez. Fajardo, Yiqing Tang
-
Publication number: 20120269722Abstract: A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: ApplicationFiled: April 20, 2012Publication date: October 25, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Peter William STRATFORD, Simon LEPPARD, Pedro GARCIA, Brenda HALL, Maria Victoria Fajardo GONZALEZ
-
Patent number: 8252878Abstract: A novel class of polymers obtainable by copolymerising a monomer mixture comprising (i) hydrophilic monomer of general formula (I) Y—B—X; (ii) styrene or a substituted styrene, a monomer or mixture of monomers which when polymerized form a polymer with a Tg lower than the Tg of a homopolymer of monomer (I) and lower than the Tg of a homopolymer of monomer (ii); and a monomer having a crosslinkable group is described. The invention also relates to a method for producing such polymers, implants coated with the polymers and methods for forming the same.Type: GrantFiled: July 16, 2007Date of Patent: August 28, 2012Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Sean Willis, Stephen Alister Jones, Vincent James O'Byrne, David Michael Grey, Michael John Driver, Samantha Ryan, Richard Paul Redman
-
Publication number: 20120201867Abstract: An embolic composition comprises microspheres formed of water-insoluble water-swellable anionic polymer having swollen diameter more than 100 ?m, and a cationic camptothecin compound, preferably irinotecan. The microspheres are preferably formed of crosslinked polyvinylalcohol, preferably of ethylenically unsaturated polyvinylalcohol macromer, crosslinked with anionic ethylenically unsaturated anionic comonomer. The compositions are used to treat hypervascular tumours for instance colorectal metastases of the liver.Type: ApplicationFiled: April 20, 2012Publication date: August 9, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Peter William STRATFORD, Maria Victoria GONZALEZ.FAJARDO, Yiqing TANG
-
Patent number: 8221793Abstract: A composition for chemoembolotherapy of solid tumors comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.Type: GrantFiled: September 15, 2008Date of Patent: July 17, 2012Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Peter William Stratford, Simon Leppard, Pedro Garcia, Brenda Hall, Maria Victoria Fajardo Gonzalez
-
Publication number: 20120178984Abstract: Provided herein are bio-absorbable strands for use in brachytherapy. In an embodiment, a plurality of discrete hollow bio-absorbable segments spaced apart from one another and encapsulated using a bio-absorbable material to form an elongated member configured to be implantable in patient tissue using a hollow needle. Each hollow bio-absorbable segment has a length, an outer periphery and an inner channel. Radioactive material is within at least a portion of the inner channel or coating at least a portion of the outer periphery of each hollow bio-absorbable segment. Contrast material is within at least a portion of the inner channel or coating at least a portion of the outer periphery of each hollow bio-absorbable segment.Type: ApplicationFiled: March 19, 2012Publication date: July 12, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Gary A. Lamoureux, James Matons
-
Publication number: 20120157550Abstract: An aqueous composition comprises an amphiphilic block copolymer, having a hydrophilic block comprising pendant zwitterionic groups and a hydrophobic block, and a biologically active compound associated with the polymer. The polymer is preferably in the form of micelles, and preferably the biological active is a hydrophobic drug. The hydrophilic block is preferably formed from acrylic monomer including phosphorylcholine groups. The hydrophobic group is suitably formed from monomer which has groups which can be ionised at useful pH's, especially tertiary amine groups. Micelles may be formed by dissolving the block copolymer in aqueous solvent at a pH at which the amine groups are protonated then raising the pH to a value at which the amine groups are substantially deprotonated, whereupon micelles spontaneously form. The preformed micelles are then contacted with active, under conditions such that solubilisation of the active occurs. The active may be for tumour treatment.Type: ApplicationFiled: January 23, 2012Publication date: June 21, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Steven Peter ARMES, Andrew W. LLOYD, Jonathan P. SALVAGE
-
Patent number: 8182802Abstract: Compositions are described comprising a of a block copolymer having an overall ionic charge and in which one of the blocks has pendant zwitterionic groups and a biologically active compound having a charge opposite that of the polymer. The polymer is preferably a linear diablock copolymer, preferably having a low polydispersity, such as a (tertiary amine group containing monomer) block-(zwitterionic monomer) copolymer. Suitable cationic monomers are dialkyl aminoalkyl(alk)acrylates and -acrylamides and suitable zwitterionic monomers are phosphorylcholine group containing acrylate monomers such as 2-methacyloyloxyetyl-21-trimethyl ammonium ethyl phosphate liner salt. The biologically active compound is generally polyionic and is for instance a nucleic acid, such as DNA, especially plasmid DNA.Type: GrantFiled: March 7, 2003Date of Patent: May 22, 2012Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Steven Peter Armes
-
Patent number: 8114007Abstract: In an embodiment a therapeutic member includes a solitary radioactive seed. The seed includes a metallic housing with radioactive material contained within the metallic housing. The metallic housing has a first longitudinal end and a second longitudinal end and a longitudinal length between the first and second longitudinal ends. A polymeric material is molded to completely and monolithically encapsulate the metallic housing of the solitary radioactive seed. The implantable therapeutic member is adapted to be implanted into patient tissue using a hollow needle. A portion of the molded polymeric material extends from one of the first and second longitudinal ends of the metallic housing to reduce a tendency of the seed to migrate and rotate within a patient's body after implantation of the member.Type: GrantFiled: December 15, 2008Date of Patent: February 14, 2012Assignee: Biocompatibles UK LimitedInventors: Gary A. Lamoureux, James Matons, Warren W. Johnston, Matthew Bouffard, Warren Rice
-
Publication number: 20120016082Abstract: An initiator for the terminal group of the polymer product of an atom or group radical transfer polymerisation has an activated carboxyl or an amine group which is reacted with an amine or carboxyl (respectively) group containing biologically active compound. The initiator is preferably 4-(3-(2-bromo, 2-methyl-propionate)phenyl)-propionic acid N-hydroxysuccinimide ester or 2-bromo, 2-methyl-propionic acid N-hydroxysuccinimide ester. The monomers preferably comprise a zwitterionic monomer such as 2-methacryloxyethyl-2?-trimethyl ammoniumethyl phosphate inner salt.Type: ApplicationFiled: September 23, 2011Publication date: January 19, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Simon William LEPPARD
-
Publication number: 20120016085Abstract: The present invention relates to conjugates of biologically active compounds, preferably therapeutically active compounds, with polymeric moieties having low polydispersity, as well as controlled polymerisation processes for producing the conjugates. An initiation for a controlled radical polymerisation process comprises a biologically active, usually therapeutically active, moiety and the monomer includes zwitterionic monomer for instance 2-methacryloyloxyethyl-2?-trimethylammonium ethyl phosphate inner salt. The process allows close control of the molecular weight and polydispersity of the polymeric moiety and the possibility of optimising the delivery characteristics of the active agent.Type: ApplicationFiled: September 23, 2011Publication date: January 19, 2012Applicant: BIOCOMPATIBLES UK LIMITEDInventor: Andrew Lennard LEWIS
-
Publication number: 20110293672Abstract: There is provided a composition comprising microspheres which comprise a water-insoluble, water-swellable polymer and associated with the polymer, in releasable form, a chemotherapeutic agent, for use in the treatment of a pancreatic tumour or cyst, wherein the microspheres, when equilibrated in water at 37° C., comprise at least 40 wt % water based on weight of polymer plus water, wherein the polymer is anionically charged at pH7 and the chemotherapeutic agent is cationically charged and electrostatically associated with the polymer. Also provided are methods of treating pancreatic tumours or cysts using this composition.Type: ApplicationFiled: November 25, 2009Publication date: December 1, 2011Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard Lewis, Peter William Stratford, Richard Edward John Forster
-
Publication number: 20110293731Abstract: A process is described for loading hydrophilic polymer particles with a water-insoluble solvent-soluble drug. The particles are preferably embolic agents. The method provides particles having little or no drug at the surface and in a surface layer, whereby the burst effect is minimised. The drug is precipitated in the core of the particle, leading to extended release. The drug is, for instance, paclitaxel, rapamycin, dexamethasone or ibuprofen.Type: ApplicationFiled: June 15, 2011Publication date: December 1, 2011Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Andrew Lennard LEWIS, Yiqing TANG, Maria Victoria GONZALEZ FAJARDO
-
Patent number: 8066627Abstract: A delivery system and method for interstitial radiation therapy comprising substantially axially stiff and longitudinally flexible elongated members made of material which is bioabsorbable in living tissue and a plurality of radioactive seeds dispersed in a predetermined array within the elongate member. The radioactive seeds can be dispersed within assembled half-shells made of the same material. The housing for the radiation seeds can also be manufactured from extruded material. A system for manufacturing the interstitial radiation therapy seed strands that automatically makes the seed strands at the patient's bedside. The delivery system and method further customize the member based on a prescription.Type: GrantFiled: June 16, 2006Date of Patent: November 29, 2011Assignee: Biocompatibles UK LimitedInventors: Richard A. Terwilliger, Gary A. Lamoureux
-
Patent number: 8053520Abstract: An initiator for the terminal group of the polymer product of an atom or group radical transfer polymerisation has an activated carboxyl or an amine group which is reacted with an amine or carboxyl (respectively) group containing biologically active compound. The initiator is preferably 4-(3-(2-bromo, 2-methyl-propionate)phenyl)-propionic acid N-hydroxysuccinimide ester or 2-bromo, 2-methyl-propionic acid N-hydroxysuccinimide ester. The monomers preferably comprise a zwitterionic monomer such as 2-methacryloxyethyl-2?-trimethyl ammoniumethyl phosphate inner salt.Type: GrantFiled: January 16, 2004Date of Patent: November 8, 2011Assignee: Biocompatibles UK LimitedInventors: Andrew Lennard Lewis, Simon William Leppard
-
Patent number: 8048408Abstract: The present invention relates to conjugates of biologically active compounds, preferably therapeutically active compounds, with polymeric moieties having low polydispersity, as well as controlled polymerisation processes for producing the conjugates. An initiation for a controlled radical polymerisation process comprises a biologically active, usually therapeutically active, moiety and the monomer includes zwitterionic monomer for instance 2-methacryloyloxyethyl -2?-trimethylammonium ethyl phosphate inner salt. The process allows close control of the molecular weight and polydispersity of the polymeric moiety and the possibility of optimizing the delivery characteristics of the active agent.Type: GrantFiled: January 16, 2003Date of Patent: November 1, 2011Assignee: Biocompatibles UK LimitedInventor: Andrew Lennard Lewis
-
Publication number: 20110263923Abstract: Spacers for use in brachytherapy, radiotherapy, and other medical therapy, which can be used to improve a patient's outcome, assist in treating difficult cases and/or combine multiple modalities that are currently performed separately into a single procedure. In accordance with an embodiment, a spacer is formed of an encapsulating material in a generally cylindrical or elongated shape. One or more regions are formed within the spacer for receiving and retaining therapeutic loads, such as radiation sources and/or pharmaceutical therapeutic loads, and/or any other substances that a physician might select to treat a patient, such as drug liquids, powder or particles (e.g., microparticles or nanoparticles), with the particles or powders combined with binders, such as polyacrylamide, that are selected to retain and gradually disperse the powder or particles at a desired rate.Type: ApplicationFiled: December 8, 2010Publication date: October 27, 2011Applicant: BIOCOMPATIBLES UK LIMITEDInventors: Gary A. Lamoureux, Warren Johnston, Lino Costantini
-
Publication number: 20110229572Abstract: A composition comprising microspheres of a polymer matrix, having two different pharmaceutical actives having complementary, usually synergistic, activity in killing cells. The compositions have particular utility for treating tumours. Useful combinations are doxorubicin with rapamycin, irinotecan with ibuprofen, ibuprofen with doxorubicin and irinotecan with doxorubicin. The polymer matrix is preferably a crosslinked polyvinyl alcohol. The drugs may be included in the same microsphere, or microspheres each with an individual pharmaceutical agent may be mixed together. The microspheres are preferably used in chemoembolisation of tumours.Type: ApplicationFiled: August 18, 2008Publication date: September 22, 2011Applicant: BIOCOMPATIBLES UK LimitedInventors: Andrew Lennard Lewis, Richard Edward John Forster, Mroa Voctoria Gonzalez-Fajardo, Yiqing Tang, Andrew Willam LLoyd, Gary John Phillips
-
Patent number: 8021291Abstract: In an embodiment, an implantable marker, which is adapted to be implanted into patient tissue using a hollow needle, includes a marker body including a radiopaque material and a polymeric material that encapsulates at least a portion of the marker body. In an embodiment, an outer surface of the encapsulating material includes one or more protrusions to reduce a tendency of the marker to migrate and rotate within a patient's body after implantation.Type: GrantFiled: January 21, 2009Date of Patent: September 20, 2011Assignee: Biocompatibles UK LimitedInventors: Gary A. Lamoureux, James Matons, Warren W. Johnston, Matthew Bouffard, Warren Rice